2025-12-22 - Analysis Report
Okay, here's a comprehensive report on Intuitive Surgical (ISRG), based on the data you provided:

**1. Return Rate Comparison (ISRG vs. VOO)**

*   **Company Overview:** Intuitive Surgical designs, manufactures, and markets the da Vinci surgical system, a robotic-assisted surgical platform.
*   **ISRG Cumulative Return:** 111.57%
*   **VOO Cumulative Return:** 100.88%
*   **Divergence:** Current divergence of 10.7, with a relative divergence of 35.5. This means ISRG is currently outperforming the S&P 500 (VOO), and the current divergence is in the lower range of its historical fluctuations compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha  | Beta  | Cap(B) |
|------------|---------|---------|--------|-------|--------|
| 2015-2017  | 68.0%   | 77.6%   | 40.0%  | -0.1 | 43.6   |
| 2016-2018  | 64.0%   | 72.2%   | 49.0%  | -0.0 | 57.2   |
| 2017-2019  | 54.0%   | 72.2%   | 31.0%  | 0.2  | 70.6   |
| 2018-2020  | -6.0%   | 80.4%   | -29.0% | 0.3  | 97.8   |
| 2019-2021  | 29.0%   | 80.4%   | -18.0% | 0.6  | 128.8  |
| 2020-2022  | -23.0%  | 80.4%   | -22.0% | 1.2  | 95.1   |
| 2021-2023  | -17.0%  | 77.5%   | -18.0% | 1.7  | 120.9  |
| 2022-2024  | 36.0%   | 77.5%   | 15.0%  | 1.7  | 187.1  |
| 2023-2025  | 74.0%   | 72.7%   | 8.0%   | 0.8  | 205.2  |

*   **CAGR:** Fluctuates significantly, indicating periods of high growth and decline. Recently, the CAGR has been very strong.
*   **MDD:** Consistently high Maximum Drawdown values suggest considerable volatility in ISRG's price.
*   **Alpha:** The Alpha value is mostly positive in earlier periods, suggesting outperformance relative to its benchmark. More recently, the Alpha is negative, indicating underperformance on a risk-adjusted basis.
*   **Beta:** The Beta value has increased over time, suggesting the stock has become more sensitive to market movements.
*   **Cap(B):** Market capitalization has generally increased over time, indicating overall growth.

**2. Recent Stock Price Fluctuations**

*   **Current Price:** $572.47
*   **Previous Close:** $561.89
*   **Change:** 1.88 (Significant price increase from the previous day)
*   **5-day SMA:** $561.06
*   **20-day SMA:** $564.08
*   **60-day SMA:** $522.79

**Analysis:** The current price is above all three moving averages, suggesting a short-term upward trend.  The substantial price increase from the previous close highlights potential volatility.

**3. RSI, PPO, Divergence, and Expected Return Analysis**

*   **MRI (Market Risk Indicator):** 0.7 (Medium Investment Recommended)
*   **RSI:** 52.71 (Neutral - Neither overbought nor oversold)
*   **PPO:** -0.34 (Slightly bearish, but close to zero)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent Divergence Change (20 days):** 8.0 (Positive, indicating short-term upward momentum)
*   **Expected Return:** 23.9% (Projected excess return over S&P 500 if held long-term)

**Analysis:** The MRI suggests a medium level of investment risk. The neutral RSI and slightly bearish PPO provide mixed signals. The strong recent price increase reinforces the short-term upward momentum suggested by the divergence change.  The high expected return is attractive for long-term investors.

**4. Recent News & Significant Events**

*   **Positive Analyst Coverage:** Multiple articles highlight price target increases from Truist and RBC Capital, indicating positive sentiment from analysts.
*   **Company Valuation and Strategy:** News articles discuss reassessing the valuation after earnings beats, FDA da Vinci clearance, and strategy shifts.
*   **Competition:** The article comparing ISRG to Medtronic highlights the competitive landscape in the robotic surgery market.
*   **Overall:** The news is predominantly positive, focusing on strong performance, analyst upgrades, and advancements in the company's technology.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 2.06 (~Buy)
*   **Number of Opinions:** 29
*   **Target Price (avg/high/low):** $599.60 / $700.00 / $378.00
*   **Recent Rating Changes:**  No recent changes are reported in the data.

**Analysis:**  A strong "Buy" consensus among analysts suggests confidence in ISRG's future performance. The average target price of $599.60 indicates potential upside from the current price.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-10-22 | 1.98  | 2.51 B$    |
| 2025-07-23 | 1.84  | 2.44 B$    |
| 2025-04-23 | 1.95  | 2.25 B$    |
| 2024-10-18 | 1.59  | 2.04 B$    |
| 2025-10-22 | 1.59  | 2.04 B$    |

**Analysis:**  The table shows a trend of increasing EPS and revenue. The most recent earnings (2025-10-22) demonstrate solid performance. Duplicated dates in the table should be checked and corrected if required.

**6. Financial Information (Revenue & Profitability, Capital & Profitability)**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $2.51B    | 66.36%        |
| 2025-06-30   | $2.44B    | 66.31%        |
| 2025-03-31   | $2.25B    | 64.69%        |
| 2024-12-31   | $2.41B    | 68.04%        |
| 2024-09-30   | $2.04B    | 67.41%        |

**Analysis:** Revenue is generally increasing, and profit margins remain very high, indicating strong operational efficiency.

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $16.93B   | 4.16%   |
| 2025-06-30   | $17.85B   | 3.69%   |
| 2025-03-31   | $17.11B   | 4.08%   |
| 2024-12-31   | $16.43B   | 4.17%   |
| 2024-09-30   | $15.58B   | 3.63%   |

**Analysis:** Equity is increasing, and ROE (Return on Equity) is relatively stable, indicating consistent profitability relative to equity.

**7. Comprehensive Analysis (Summary)**

Intuitive Surgical (ISRG) presents a mixed but generally positive outlook.

*   **Strengths:**
    *   Outperformance relative to the S&P 500 (VOO).
    *   Strong revenue and profit margins.
    *   Positive analyst sentiment with a "Buy" consensus and potential upside in target price.
    *   Recent positive news coverage, including analyst upgrades and company advancements.
    *   Increasing EPS and revenue trends.
    *   High expected return for long-term investment.
*   **Weaknesses/Concerns:**
    *   High Maximum Drawdown values indicate significant volatility.
    *   Negative Alpha in recent years indicates underperformance on a risk-adjusted basis compared to its benchmark.
    *   Increasing Beta suggests greater sensitivity to market fluctuations.
    *   The significant price increase from the previous day, indicates high volatility.
    *   The analysis relies on the assumption that the provided data is accurate and free of errors (e.g., the duplicate date in the earnings table).
    *   The "Medium Investment Recommended" MRI, while not inherently negative, isn't as strong of a signal as a "High Investment Recommended" rating.
*   **Overall Assessment:**

ISRG is a growth stock with high potential returns, but also considerable risk. The company's strong fundamentals, positive analyst outlook, and recent positive news suggest a favorable outlook. However, investors should be aware of the stock's volatility and sensitivity to market movements. A long-term investment horizon is likely more suitable given the expected returns. The recent relative divergence change indicates a short-term upward trend.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.